Compare STSS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STSS | SCLX |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | 55 | 34 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 48.5M |
| IPO Year | N/A | N/A |
| Metric | STSS | SCLX |
|---|---|---|
| Price | $1.84 | $8.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 169.6K | 92.3K |
| Earning Date | 04-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $4.20 |
| 52 Week High | $18.23 | $34.27 |
| Indicator | STSS | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 58.11 |
| Support Level | $1.66 | $7.73 |
| Resistance Level | $2.00 | $9.51 |
| Average True Range (ATR) | 0.11 | 0.96 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 25.00 | 68.54 |
Sharps Technology Inc is a medical device and pharmaceutical packaging company offering patented, smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities that incorporate syringe technologies that use both passive and active safety features. The Company has adopted a digital asset treasury scheme focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.